{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:01:05Z","timestamp":1758052865595,"version":"3.44.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T00:00:00Z","timestamp":1719705600000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clinbiochem.2023.110601","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T21:19:03Z","timestamp":1687382343000},"page":"110601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Pharmacokinetics of baricitinib in critically ill COVID-19 patients"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5828-0197","authenticated-orcid":false,"given":"Nicolas","family":"Massart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Fillatre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0908-3629","authenticated-orcid":false,"given":"Florian","family":"Lemaitre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Mari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1030-1750","authenticated-orcid":false,"given":"Camille","family":"Tron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clinbiochem.2023.110601_b0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and Safety of Baricitinib plus Standard of Care for the Treatment of Critically Ill Hospitalised Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: An Exploratory, Randomised, Placebo-Controlled Trial","volume":"10","author":"Ely","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.clinbiochem.2023.110601_b0010","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and Safety of Baricitinib for the Treatment of Hospitalised Adults with COVID-19 (COV-BARRIER): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.clinbiochem.2023.110601_b0015","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-022-04205-8","article-title":"Efficacy and Safety of Baricitinib in Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"27","author":"Tr\u00f8seid","year":"2023","journal-title":"Crit. Care"},{"issue":"2","key":"10.1016\/j.clinbiochem.2023.110601_b0020","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cpt.936","article-title":"Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients","volume":"104","author":"Kim","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.clinbiochem.2023.110601_b0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/cpt.2600","article-title":"Physiologically-Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID-19 in Geriatrics","volume":"112","author":"Wang","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.clinbiochem.2023.110601_b0030","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"10.1016\/j.clinbiochem.2023.110601_b0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3797\/scipharm.1510-08","article-title":"Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS\/MS: Application to a Pharmacokinetic Study","volume":"84","author":"Veeraraghavan","year":"2016","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.clinbiochem.2023.110601_b0040","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41564-023-01356-4","article-title":"Therapeutics for COVID-19","volume":"8","author":"Toussi","year":"2023","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.clinbiochem.2023.110601_b0045","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/cts.12486","article-title":"Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib","volume":"10","author":"Posada","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.clinbiochem.2023.110601_b0050","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","article-title":"The Pharmacokinetics, Pharmacodynamics, and Safety of Baricitinib, an Oral JAK 1\/2 Inhibitor, in Healthy Volunteers","volume":"54","author":"Shi","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.clinbiochem.2023.110601_b0055","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/cpdd.77","article-title":"Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Renal and Hepatic Impairment Patients","volume":"3","author":"Chen","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"6","key":"10.1016\/j.clinbiochem.2023.110601_b0060","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/0091270011405663","article-title":"The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers","volume":"52","author":"Shi","year":"2012","journal-title":"J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2023.110601_b0065","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1097\/CCM.0000000000005682","article-title":"Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome","volume":"50","author":"Rein","year":"2022","journal-title":"Crit. Care Med."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912023001297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912023001297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T16:01:28Z","timestamp":1757865688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912023001297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":13,"alternative-id":["S0009912023001297"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2023.110601","relation":{},"ISSN":["0009-9120"],"issn-type":[{"type":"print","value":"0009-9120"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of baricitinib in critically ill COVID-19 patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2023.110601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of The Canadian Society of Clinical Chemists.","name":"copyright","label":"Copyright"}],"article-number":"110601"}}